
Three targeted inhibitors offer new strategies for HR-positive, HER2-negative breast cancer with PIK3CA mutations.
Three targeted inhibitors offer new strategies for HR-positive, HER2-negative breast cancer with PIK3CA mutations.
BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
Second-line and later treatment options for small cell lung cancer are limited.
These combination therapies have demonstrated longer PFS with a tolerable AE profile.